Stock KPTI KARYOPHARM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.13 USD +4.63% Intraday chart for Karyopharm Therapeutics Inc. +6.60% +30.64%
Apr. 24 Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting CI
Mar. 13 Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
Karyopharm Therapeutics : April 19, 2024
PU
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Karyopharm Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
AQ
Karyopharm Therapeutics: Q4 Earnings Snapshot
AQ
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor -Naive Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
AQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Karyopharm to Participate at Upcoming Investor Conferences
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KPTI Stock
  4. News Karyopharm Therapeutics Inc.
  5. Press Releases